• Site lead for a team responsible for developability assessment of compounds coming from research programs across seven disease areas requiring formulations for oral, parenteral or topical delivery. Collaborate with portfolio managers in each disease area to understand future trends, likely resource demands and get feedback for our team.• Lead a group of seven full time and up to three contract lab staff. Coach and mentor team members on technical subjects and project team interactions and dynamics. Responsible for personal and career development of team members.

• CMC lead for small molecule projects. Lead a matrix team responsible for activities to deliver drug substance and drug product for Phase I studies. • Partner with global project teams to develop and implement an appropriate technical and development strategy from candidate selection through proof of concept.

• Effective member of cross functional discovery and development project teams, having worked on multiple preclinical projects providing an in depth evaluation of the developability of molecules including selection of physical form and formulation approach for development• Led development of a working model for transition of new topical ocular projects. Aligned expectations with key local customers and communicated with key stakeholders to present proposed workflow. Developed logistics of formulation development and shipment and developed platform formulation for topical ocular delivery

• Support discovery teams by providing expertise in preclinical formulation development, from simple suspensions and solutions for early PK and safety studies to solid dispersions and microemulsions for poorly water soluble compounds• Key contributor to the development and implementation of groups global approach to physical form characterization, salt screening and solid dispersion screening • Developed several cross-functional alliances, including with in vitro ADME and analytical sciences groups

Examined the effect of counter ion on the amorphous properties of organic salts using moisture sorption, DSC, Raman, and optical microscopyCompleted salt form screen for the model compounds using the Symyx® high throughput crystallization apparatusElucidated structural information relating to pre-nucleation aggregates of polymorphic drug substances using vibrational, UV and NMR spectroscopy to characterize solutions

Use of additives to control particle size and morphology to successfully crystallize nanoparticles.